Julie E. Irving

Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Journal: Cancer cell international
Published: November 07, 2025

First-year results of the International Leukemia/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.

First-year results of the International Leukemia/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.

Journal: Haematologica
Published: November 04, 2025

Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia.

Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia.

Journal: Cancers
Published: November 12, 2024

Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Journal: Leukemia
Published: October 05, 2023

Selection of dormant cells during treatment of T-lineage lymphoblastic leukemia and CREB as a therapeutic target.

Selection of dormant cells during treatment of T-lineage lymphoblastic leukemia and CREB as a therapeutic target.

Journal: Haematologica
Published: September 26, 2023

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Journal: Cancer cell international
Published: July 26, 2023

Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia.

Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma
Published: October 22, 2022

Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia.

Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia.

Journal: Haematologica
Published: June 21, 2022

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.

Journal: BMJ open
Published: March 05, 2022

Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature.

Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature.

Journal: British journal of haematology
Published: October 18, 2021

The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia.

The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia.

Journal: Cancer medicine
Published: December 24, 2020

Label-Free Leukemia Monitoring by Computer Vision.

Label-Free Leukemia Monitoring by Computer Vision.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology
Published: November 12, 2019
Showing 1-12 of 34

Last Updated: 09/26/2026